Poïesis Therapeutics is a biotechnology start-up focused on sourcing and in-licensing innovative late stage therapeutics and diagnostics from human biomedical research and developing them to address unmet needs in the veterinary market for companion animals – horses, dogs and cats.
Our mission statement adheres to the “one health” concept, reflective of the inherent synergies between animal and human medicine.
Developing new medicines to address unmet needs in animal health.
Developing new veterinary diagnostics to identify disorders in dogs, cats and horses.
Corporate Social Responsibility
Poïesis contributes a percentage of its profits to chosen charities which are making a difference for humans and animals.
By Arlene Weintraub, FiercePharma Animal Health, August 29, 2016. Shares of animal health companies are outperforming the stock market as a whole, thanks largely to strong performances from companies like diagnostics maker IDEXX Laboratories ($IDXX), veterinary...read more
By Cathy Yarbrough, Contributing Editor, Life Science Leader, July 1, 2016. The animal health industry is on a growth trajectory, powered by the popularity of pet ownership and a global population hungry for meat and dairy products. The many large and small...read more
By K9 Magazine, April 6, 2016. Almost any dog owner who has lost a beloved dog to cancer has probably faced the reality that we do not yet have the same plethora of advanced treatments available for our four-legged friends that we have for people. Yet, our dogs share...read more
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.